Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Rande Is . . . HOME -- Ignore unavailable to you. Want to Upgrade?

To: Bucky Katt who wrote (12503)	9/21/1999 9:29:00 AM
From: Rande Is	Respond to of 57584

AAPL getting haircut on pre-market. . . enormous volume. . .1.3 mil traded already. Stocks headed up at the bell. . . IMGN GNLB . . . Great job, William! BBBY CORL BAMB Everything else? Well wash it. . .rinse it. . .shake it out. . .steal it? Rande Is

To: Bucky Katt who wrote (12503)	9/21/1999 9:57:00 AM
From: BANCHEE	Respond to of 57584

William News on IMGN Tuesday September 21, 9:05 am Eastern Time Company Press Release SOURCE: ImmunoGen, Inc. ImmunoGen, Inc. Investigational New Drug Application for huC242-DM1/SB-408075 Accepted by FDA --ImmunoGen, Inc. reaches third milestone in collaboration with SmithKline Beecham, triggering $4 million payment-- NORWOOD, Mass., Sept. 21 /PRNewswire/ -- ImmunoGen, Inc. (Nasdaq: IMGN - news) today announced that its Investigational New Drug application (''IND'') for huC242-DM1/SB-408075, its lead tumor activated prodrug for the treatment of colorectal and pancreatic cancers, has been accepted by the FDA. This acceptance is the third milestone to be achieved in ImmunoGen's collaboration with SmithKline Beecham plc (''SB'') and triggers a payment of $4 million from SB. To date, ImmunoGen has earned $7 million from SB in milestone payments. ImmunoGen expects to initiate human studies of huC242-DM1/SB-408075 by the end of this year in patients suffering from refractory colorectal cancer. Patients suffering from refractory pancreatic cancer will also be included, based on laboratory tests conducted this year demonstrating the affinity of the huC242 antibody to pancreatic tumor cells as well as colorectal cancer cells. ''Our collaboration with SB has provided a solid foundation for growth and contributes to the momentum that has resulted in our steady achievement of several milestones. Included in this, of course, is the acceptance by FDA of our IND application,'' said Mitchel Sayare, Ph.D., Chairman and CEO of ImmunoGen, Inc. ''We are encouraged by the promising animal data for huC242- DM1/SB-408075, and we look forward to assessing this product in humans later this year. We believe that huC242-DM1/SB-408075 holds the promise to provide patients with a more potent, less toxic treatment for these lethal forms of cancer.'' The collaboration between ImmunoGen and SB was executed in February of 1999. Under terms of the agreement, ImmunoGen can receive up-front cash and milestone payments totaling more than $40 million. SB received worldwide rights to commercialize huC242-DM1/SB-408075, except in certain Far East territories. SB and ImmunoGen are collaborating on the remaining development. ImmunoGen will direct the product's initial assessment in humans. ImmunoGen, Inc. develops innovative biopharmaceuticals, primarily for cancer treatment. The Company has created potent tumor-activated prodrugs, consisting of drugs coupled to monoclonal antibodies, for delivery to and destruction of cancer cells. This press release includes forward-looking statements based on management's current expectations. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the ability to secure future funding; the success of the Company's research strategy; the applicability of the discoveries made therein; the difficulties inherent in the development of pharmaceuticals, including uncertainties as to the timing and results of preclinical studies; delayed achievements of milestones; reliance on collaborators; uncertainty as to whether the Company's potential products will succeed in entering human clinical trials and uncertainty as to the results of such trials; uncertainty as to whether adequate reimbursement for these products will exist from government, private healthcare insurers and third-party payors; and the uncertainties as to the extent of future government regulation of the pharmaceutical business. SOURCE: ImmunoGen, Inc.

To: Bucky Katt who wrote (12503)	9/21/1999 10:00:00 AM
From: BANCHEE	Read Replies (1) \| Respond to of 57584

William News GNLB Tuesday September 21, 8:28 am Eastern Time Genelabs lupus drug trial positive REDWOOD CITY, Calif., Sept 21 (Reuters) - Genelabs Technologies Inc. said Tuesday that results of its second Phase III clinical trial of GL701, its investigational drug for lupus, were positive. The biopharmaceutical company said that it intends to submit a New Drug Application for the drug to the U.S. Food and Drug Administration. The study, which enrolled 381 women with systemic lupus erythematosus (SLE), was designed to determine whether GL701 can improve or stabilize clinical outcome and disease symptoms in people with SLE. SLE, a disease that primarily affects women, causes the immune system attacks the body's own tissue, which can lead to inflammation, pain and injury to tissues and major organs. Common symptoms include severe fatigue, arthritis, facial rash and unusual sensitivity to sunlight. About 200,000 people suffer from SLE in the United States and more than 1 million have it worldwide. Genelabs completed its first Phase III trial with GL701 in 1997. In the first study, steroid-dependent SLE patients had a higher rate of response to treatment with GL701 than patients on placebo, demonstrated by sustained reduction of their prednisone dose to physiologic levels. Genelabs' therapeutic approach with GL701, through an exclusive license from Stanford University, is to increase levels of dehydroepiandrosterone (DHEA) in patients with SLE. GL701 is a pharmaceutical preparation that contains prasterone, the pharmaceutical generic designation for DHEA, as the active ingredient. DHEA is a naturally occurring hormone that is produced by the adrenal glands, but people with SLE generally have abnormally low levels of DHEA. Earlier this year the FDA granted Fast Track designation to GL701 for SLE, which means that the FDA has determined that GL701 is intended to treat a serious or life-threatening condition for which there is no adequate therapy currently available. In 1994, GL701 received Orphan Drug designation from the FDA for the treatment of SLE, which provides seven years of marketing exclusivity from the date of a drug's approval. Genelabs said it intends to retain the right to market GL701 in the United States and is seeking partners for development and marketing of GL701 outside of the United States.